Is there a Mounjaro pill? What's available in Spain and what's happening with Lilly's pill

No, there's no Mounjaro pill. Tirzepatide, its active ingredient, is only sold in Spain as a once-weekly injection, and the AEMPS medicines register lists no oral form. The AEMPS is the Spanish Agency of Medicines and Medical Devices. The 'Lilly pill' people are talking about is a different medicine, orforglipron (Foundayo). The US Food and Drug Administration (FDA) approved it in the United States on 1 April 2026, but in the European Union it's still waiting for a decision from the European Commission, and it isn't sold in Spain. The tablets you can get in Spain today are Wegovy, which needs a prescription, and Rybelsus, which is for type 2 diabetes only.

Is there an oral version of tirzepatide?

No. In CIMA, the AEMPS medicines database, every tirzepatide product is a solution for injection, in a pen, a vial or a KwikPen. The ones marketed in Spain are Mounjaro KwikPen pens in 2.5, 5, 7.5, 10, 12.5 and 15 mg doses. Each pen holds four doses and, because it's injected once a week, lasts four weeks.

Tirzepatide is a dual agonist: it acts on both the GIP receptor and the GLP-1 receptor, as described in its main obesity trial, SURMOUNT-1. No form of this molecule that is taken by mouth appears in the register. So any product advertised as 'Mounjaro capsules' or 'oral tirzepatide' is not an authorised medicine in Spain, even if it uses the brand name or the name of the active ingredient.

What is the Lilly pill everyone is talking about?

It's orforglipron, which Lilly sells in the United States as Foundayo. It isn't tirzepatide in a different form but a different molecule. It's a small, non-peptide molecule that acts only on the GLP-1 receptor. The FDA approved it on 1 April 2026 for adults with obesity, or with overweight and weight-related health problems, alongside a reduced-calorie diet and more physical activity.

What sets it apart from other tablets in its class is how you take it. According to Lilly, it's taken once a day, at any time, with no rules about food or water. If you'd like more detail on how it works and why it has attracted so much interest, we cover it in what orforglipron is and why it isn't available in Spain.

When will orforglipron reach Spain?

There's no official date. On 15 October 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion. It recommended authorising Foundayo in adults for weight management and for type 2 diabetes. That opinion is a recommendation, not an authorisation. As of 5 November 2026, the EMA still lists it as waiting for a European Commission decision, and no medicine containing orforglipron appears in CIMA.

At least two steps are still needed before a Spanish pharmacy can dispense it. First, the European Commission has to grant the marketing authorisation. Second, Lilly has to launch it in Spain, with a CIMA entry and a price. Neither step has an announced date.

Wegovy tablets give a useful point of reference, though not a prediction. They received a positive CHMP opinion in May 2026, and Novo Nordisk announced European Commission authorisation on 15 July. CIMA recorded the authorisation on 22 July and, according to press reports, the tablets reached Spanish pharmacies on 1 November. Each medicine follows its own timetable.

For weight management, the CHMP has proposed the same indication as other treatments in this class. It covers adults with a BMI of 30 or more, or a BMI from 27 up to 30 with at least one weight-related condition, alongside diet and physical activity.

How much weight did people lose on orforglipron in its trial?

The key obesity trial is ATTAIN-1, published in the New England Journal of Medicine in 2025. It followed 3,127 adults without diabetes for 72 weeks, all with obesity or with overweight and a related health condition. Average body weight fell by 7.5% on 6 mg, 8.4% on 12 mg and 11.2% on 36 mg of orforglipron, compared with 2.1% on placebo. On the highest dose, 54.6% of participants lost at least 10% of their weight and 36.0% lost at least 15%.

The most common side effects were digestive, mostly mild or moderate. They led 5.3% to 10.3% of people taking orforglipron to stop treatment, compared with 2.7% on placebo. One point not to mix up: 6, 12 and 36 mg were the doses used in the trial. The tablets listed by the EMA come in different strengths, from 0.8 to 17.2 mg.

Which tablets can you get in Spain today?

There are two, and they're approved for different conditions. The first is Wegovy tablets (oral semaglutide), the first GLP-1 agonist tablet authorised for weight management across the EU. CIMA lists four strengths, 1.5, 4, 9 and 25 mg, in packs of 30 tablets, and as of 5 November 2026 shows all of them as marketed. Its summary of product characteristics (SmPC) approves it for adults with a BMI of 30 or more, or a BMI from 27 up to 30 with at least one weight-related condition, alongside diet and physical activity.

In its 64-week OASIS 4 trial, average weight fell by 13.6% on 25 mg compared with 2.2% on placebo. Unlike orforglipron, the SmPC says to take it on an empty stomach with a sip of water. You then wait at least 30 minutes before eating, drinking or taking other medicines, because otherwise less of the drug is absorbed. It needs a prescription and isn't funded by Spain's National Health System. According to press reports, the 25 mg pack costs around €236. No official price has been published for the lower starting doses.

The second is Rybelsus, which is also oral semaglutide. However, its SmPC only approves it for type 2 diabetes that isn't well controlled, not for obesity. According to the Ministry of Health's Nomenclátor (the official price list), a pack of 30 tablets costs €123.53. It's only funded with prior authorisation (visado), for people with type 2 diabetes and a BMI of 30 or more who take it alongside other antidiabetic drugs. You'll find the cost of each dose in the price of Rybelsus in Spain.

What if someone is selling 'Mounjaro pills'?

Whatever they're selling isn't Mounjaro or any other authorised medicine. In Spain, prescription-only medicines can't be sold by post or online. This is set out in article 3.5 of the Spanish Law on Guarantees and Rational Use of Medicines (Ley de garantías y uso racional de los medicamentos). Legal online sales are limited to authorised pharmacies selling non-prescription medicines.

In September 2025, the AEMPS passed on a warning from the EMA and the network of European medicines agencies (HMA). It concerned a sharp rise in illegal products sold as GLP-1 agonists, including tirzepatide, often on fraudulent websites and promoted on social media. These products may not contain the active ingredient they claim to, and they may contain harmful levels of other substances. We explain the legal ways to get these treatments in how to get Ozempic and Mounjaro legally in Spain.

If it's Mounjaro you're after, how is it used and how much does it cost?

Mounjaro is authorised in Spain for type 2 diabetes and for weight management. For weight management, it's approved for adults with a BMI of 30 or more, or a BMI from 27 up to 30 with at least one related health condition, alongside diet and physical activity. According to its SmPC, you inject it under the skin once a week, at any time of day, with or without food. It needs a prescription and isn't funded. BIFIMED, the Ministry of Health's database of funded medicines, has listed every dose as not funded since 1 July 2024.

SURMOUNT-1 was a 72-week trial in 2,539 adults without diabetes. Average weight fell by 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, compared with 3.1% on placebo. These figures shouldn't be lined up against the ATTAIN-1 results as if it were a race. They come from separate trials with different populations and designs.

Because it isn't funded, the manufacturer sets the price freely and the Ministry's Nomenclátor doesn't publish it. We break down the cost per dose and per month in how much Mounjaro costs per month in Spain.

Until an oral tirzepatide arrives, the tablets authorised in Spain are summarised in our guide to prescription weight-loss pills in Spain.

For now, all the GLP-1 pills sold in Spain contain semaglutide: Rybelsus or oral Wegovy explains which of the two is approved for weight loss.

What to be clear about before you decide

There's currently no tablet version of this medicine. Lilly's pill is a different molecule that doesn't yet have European authorisation or a launch date in Spain. But you don't have to wait for it. If you want to lose weight with medical help, you can already get medical weight-loss treatment in Spain. AiON offers exactly that: an initial assessment, a prescription from a registered doctor where appropriate, and ongoing follow-up. You can:

Check whether you're eligible in a few minutes